Mosaicism and Chimerism

Definitions And Core Concepts

• Mosaicism refers to the presence of two or more genetically distinct cell populations within a single individual, all originating from a single zygote. This results from post-zygotic mutational events during mitotic divisions in embryonic or fetal life.
• Chimerism defines the presence of two or more genetically distinct cell populations within a single individual, originating from different zygotes. This typically arises from the fusion of dizygotic embryos, placental cell exchange, or iatrogenic transfer.

Pathophysiology And Mechanisms

Mosaicism Mechanisms

• Post-Zygotic Mutations: Chromosomal non-disjunction, anaphase lag, point mutations, deletions, or duplications occur after fertilization.
• Developmental Timing: The timing dictates the phenotype; early embryonic mutations yield widespread mosaicism, whereas late mutations produce segmental or localized disease.
• Tissue Distribution: Cell migration and proliferation patterns dictate the distribution, classically following Blaschko lines in skin manifestations.
• Germline Mosaicism: The mutation is strictly confined to gonadal precursor cells, rendering the parent phenotypically normal but harboring a significant transmission risk to offspring.
• Epigenetic Mosaicism: Involves post-zygotic imprinting defects or uniparental disomy, notably paternal UPD 11p15 in Beckwith-Wiedemann syndrome.

Chimerism Mechanisms

• Tetragametic Chimerism: Early fusion of two distinct dizygotic zygotes forms a single embryo possessing four parental genomes.
• Blood Chimerism: Vascular anastomoses in monochorionic twins facilitate blood cell exchange.
• Microchimerism: Transplacental cell trafficking or maternal-fetal microchimerism.
• Iatrogenic Chimerism: Occurs post-allogeneic hematopoietic stem cell transplantation.

Clinical Features And Pediatric Syndromes

Diagnostic Evaluation

• Clinical Prompts: Suspect mosaicism or chimerism in patients demonstrating Blaschko-line skin lesions, body asymmetry, hemihypertrophy, discordant twin phenotypes, or ambiguous genitalia.
• Karyotyping: Analyze peripheral blood examining a minimum of 20-50 metaphases to detect low-level ( $\ge$ 5-10%) mosaicism. If blood is unyielding, utilize skin fibroblasts, buccal smears, or gonadal tissue.
• Fluorescence In Situ Hybridization (FISH): Highly sensitive for detecting 1-5% mosaicism; utilizes tissue-specific probes, critical for sex chromosome mosaicism or 12p in Pallister-Killian.
• Next-Generation Sequencing: Employs high depth (>1000x) targeted panels to identify low-allele-frequency somatic variants (1-5%), preferred for GNAS, AKT1, and PIK3CA defects.
• Chimerism Testing: Short-tandem-repeat or single nucleotide polymorphism genotyping across multiple tissues (blood, skin, hair roots) is mandatory; demonstrating four parental alleles unequivocally confirms tetragametic chimerism.

Management And Surveillance

• Surgical And Orthopedic Interventions: Corrective procedures for limb overgrowth in Proteus syndrome, macroglossia reduction in Beckwith-Wiedemann syndrome, and management of fibrous dysplasia fractures.
• Endocrine Management: Aromatase inhibitors or selective estrogen receptor modulators for precocious puberty in McCune-Albright syndrome.
• Neoplastic Surveillance: Stringent abdominal ultrasound and alpha-fetoprotein monitoring for embryonal tumors in Beckwith-Wiedemann syndrome. Prophylactic gonadectomy is mandated for streak or dysgenetic gonads containing Y chromosome material due to a 5-30% lifetime gonadoblastoma risk.
• Chimerism Specifics: Gender assignment relies on gonadal function potential; involves lifelong hormone replacement and fertility counseling.

Comparison